Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: The role of granulocyte colony-stimulating factor

Clinical Infectious Diseases

Volumn 30, Issue 2, 2000, Pages 256-260

  Kuritzkes, Daniel R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BACTERIAL INFECTION; CYTOKINE RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; RISK FACTOR;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTERIAL INFECTIONS; FEMALE; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; IMMUNOCOMPROMISED HOST; MALE; NEUTROPENIA; NEUTROPHILS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0034063921     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313642     Document Type: Article

References (66)

1. 1. Gilks CF, Brindle RJ, Otieno LS, et al. Life-threatening bacteremia in HIV-1-seropositive adults admitted to a hospital in Nairobi, Kenya. Lancet 1990; 336:545-9.
2. 2. Fichtenbaum CJ, Woeltje KF, Powderly WG. Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis 1994; 19:417-22.
3. 3. Bernstein L, Krieger BZ, Novick B, Sicklick MJ, Rubinstein A. Bacterial infection in the acquired immunodeficiency syndrome of children. Pediatr Infect Dis 1985; 4:472-5.
4. 4. Krumholz HM, Sande MA, Lo B. Community-acquired bacteremia in patients with AIDS: clinical presentation, bacteriology and outcome. Am J Med 1989; 86:776-9.
5. 5. Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 1988; 158:1268-76.
6. 6. Pitrak DL. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on the bactericidal functions of neutrophils. Curr Opin Hematol 1997; 4:183-90.
7. 7. Miles SA, Mitsuyasu RT, Moreno J, et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991; 77:2109-17.
8. 8. Pitrak DL, Mullane K, Bilek M, et al. Filgrastim (r-metHuG-CSF) treatment of HIV-infected patients improves neutrophil function [abstract ThB.4181]. In: Program and abstracts of the 11th International Conference on AIDS (Vancouver), 7-12 July 1996.
9. 6/L [abstract We.A.3094]. In: Program and abstracts of the 11th International Conference on AIDS (Vancouver), 7-12 July 1996.
10. 10. Aboulafia DM, Mitsuyasu RT. Hematologic abnormalities in AIDS. Hematol Oncol Clin North Am 1991; 5:195-214.
11. 11. Doweiko JP, Groopman JE. The hematological consequences of HIV infection. In: Broder S, Merigan TC, Bolognesi D, eds. Textbook of AIDS medicine. Baltimore: Williams & Wilkins, 1994:617-25.
12. 12. Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. AIDS 1996; 10:1627-33.
13. 13. Castella A, Croxson TS, Mildvan D, Witt DH, Zalusky R. The bone marrow in AIDS: a histologic, hematologic, and microbiologic study. Am J Clin Pathol 1985; 84:425-32.
14. 14. Moses AV, Williams S, Heneveld ML, et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 1996; 87:919-25.
15. 15. Pluda JM, Mitsuya H, Yarchoan R. Hematologic effects of AIDS therapies. Hematol Oncol Clin North Am 1991; 5:229-48.
16. 16. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317:192-8.
17. 17. Sawka CA, Shepher FA, Brandwein J, et al. Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve-week chemotherapy program. Leuk Lymphoma 1992; 8:213-20.
18. 12 and transcobalamin levels in early HIV disease. Am J Hematol 1994; 47:167-71.
19. 19. Donahue RE, Johnson MM, Zon LI, Clark SC, Groopman JE. Suppression of in vitro hematopoiesis following human immunodeficiency virus infection. Nature 1987; 326:200-3.
20. 20. Pitrak DL, Tsai HC, Mullane KM, et al. Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. J Clin Invest 1996; 98: 2714-9.
21. 21. Lehrer RI, Ganz T, Selsted ME, et al. Neutrophils and host defense. Ann Intern Med 1988; 109:127-42.
22. 22. Sawyer DW, Donowitz GR, Mandell GL. Polymorphonuclear neutrophils: an effective antimicrobial force. Rev Infect Dis 1989; 11(Suppl 7): S1532-44.
23. 23. Roilides E, Mertins S, Eddy J, et al. Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type I and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor. J Pediatr 1990; 117:531-40.
24. 24. Elbim C, Prevot MH, Bouscarat F, et al. Polymorphonuclear neutrophils from human immunodeficiency virus-infected patients show enhanced activation, diminished fMLP-induced L-selectin shedding, and an impaired oxidative burst after cytokine priming. Blood 1994; 84:2759-66.
25. 25. Pitrak DL, Bak PM, DeMarais P, et al. Depressed neutrophil superoxide production in human immunodeficiency virus infection. J Infect Dis 1993; 167:1406-10.
26. 26. Neilsen H, Kharzami A, Faber V. Blood monocyte and neutrophil functions in acquired immunodeficiency syndrome. Scand J Immunol 1986; 24:291-6.
27. 27. Murphy PM, Lane HC, Fauci AS, et al. Impairment of neutrophil bactericidal capacity in patients with AIDS. J Infect Dis 1988; 158:627-30.
28. 28. Whyte MKB, Meagher LC, MacDermot, et al. Impairment of function in aging neutrophils is associated with apoptosis. J Immunol 1993; 150: 5124-34.
29. 29. Metcalf D. Hematopoietic regulators: redundancy or subtlety? Blood 1993; 82:3515-23.
30. 30. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cells deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737-46.
31. 31. Cheers C, Haigh AM, Kelso A, Metcalf D, Stanley ER, Young AM. Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSFs. Infect Immun 1988; 56:247-51.
32. 32. Tanaka H, Ishikawa K, Nishino M, et al. Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J Trauma 1996; 40:718-25.
33. 33. Cebon J, Layton JE, Maher D, et al. Endogenous hematopoietic growth factors in neutropenia and infection. Br J Haematol 1994; 86:265-74.
34. 34. Chatta GS, Price TH, Allen RC, et al. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming units in healthy young and elderly adult volunteers. Blood 1994; 84:2923-9.
35. 35. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1:667-72.
36. 36. Gabrilove JL, Jakubowski A, Fain K, et al. Phase 1 study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988; 82:1454-61.
37. 37. Lindemann A, Herrmann F, Oster W, et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989; 74:2644-51.
38. 38. Balazovich KJ, Almeida HI, Boxer LA. Recombinant human G-CSF and GM-CSF prime neutrophils for superoxide production through different signal transduction mechanisms. J Lab Clin Med 1991; 118:576-84.
39. 39. Weisbart RH, Kacena A, Schu A, et al. GM-CSF induces human neutrophil IgA phagocytosis by an IgA Fc receptor activation mechanism. Nature 1988; 332:647-8.
40. 40. de Hass M, Kerst JM, van der School CE, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on neutrophils. Blood 1994; 84:3885-94.
41. 41. Yuou A, Kitagawa S, Ohsaka A, et al. Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: potentiation of responses triggered by receptor-mediated agonists. Blood 1989; 74:2144-9.
42. 42. Allen RC, Stevens PR, Price TH, et al. In vivo effects of recombinant human granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers. J Infect Dis 1997; 175:1184-92.
43. 43. Wang JM, Collela S, Allavena P, et al. Chemotactic activity of human recombinant granulocyte-macrophage colony-stimulating factor. Immunology 1987; 60:439-44.
44. 44. Azzara A, Carulli B, Rizzuti-Gullaci A, Minnucci S, Capochiani E, Ambrogi F. Motility of rhG-CSF-induced neutrophils in patients undergoing chemotherapy: evidence for inhibition detected by image analysis. Br J Haematol 1996; 92:161-8.
45. 45. Addison IE, Johnson B, Devereux S, et al. Granulocyte-macrophage colony-stimulating factor may inhibit neutrophil migration in vivo. Clin Exp Immunol 1989; 76:149-53.
46. 46. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996; 88:335-40.
47. 47. Baldwin GC, Fuller ND, Roberts RL, et al. Granulocyte-and granulocyte-macrophage colony-stimulating factors enhance neutrophil cytotoxicity toward HIV-infected cells. Blood 1989; 74:1673-7.
48. 48. Liles WC. Granulocyte colony-stimulating factor (G-CSF) administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997; 175:1012-5.
49. 49. Shimono N, Okada K, Takeda D, et al. Granulocyte colony-stimulating factor does not enhance phagocytosis or microbicidal activity of human mature polymorphonuclear neutrophils in vitro. Clin Diagn Lab Immunol 1994; 1:556-62.
50. 50. Mauss S, Steinmetz HT, Willers R, et al. Induction of granulocyte colony-stimulating factor by acute febrile infection but not by neutropenia in HIV-seropositive individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:430-4.
51. 51. Hober D, Ajana F, Petit MC, et al. Granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha in patients with human immunodeficiency virus (HIV) type I infection. Microbtol Immunol 1993; 37:785-92.
52. 52. Herold M, Meise U, Gunther V, et al. Serum concentrations of circulating endogenous granulocyte-macrophage colony-stimulating factor in HIV-1-seropositive injecting drug users. Presse Med 1994; 23:1854-8.
53. 53. Hengge UR, Brockmeyer NH, Goos M. Granulocyte colony-stimulating factor treatment in AIDS patients. Clin Investig 1992; 70:922-6.
54. 54. Kimura S, Matsuda J, Ikematsu S, et al. Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS. AIDS 1990; 4:1251-5.
55. 55. Mueller BU, Jacobsen F, Butler KM, et al. Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. J Pediatr 1992; 121:797-802.
56. 56. Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized multicenter controlled trial. AIDS 1998; 12:65-74.
57. 57. Buhles WC Jr, Mastre BJ, Tinker AJ, Strand V, Koretz SH. Ganciclovir treatment of life-or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988; 10(Suppl 3):S495-S06.
58. 58. Mills J, Jacobson MA, O'Donnell JJ, Cederberg D, Holland GN. Treatment of cytomegalovirus retinitis in patients with AIDS. Rev Infect Dis 1988; 10 (Suppl 3):S522-31.
59. 59. Buckley RM, Braffman MN, Stern I. Opportunistic infections in the acquired immunodeficiency syndrome. Semin Oncol 1990; 17:335-49.
60. 60. Torres RA, Franke-Ruta B, Barr MR. Future therapies in the management of critically ill patients. Crit Care Clin 1993; 9:153-76.
61. 61. Jacobson MA, Liu CR, Davies D, Cohen PT. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med 1997; 157:1825-31.
62. 62. Shaunak S, Bartlett JA. Zidovudine-induced neutropenia: are we too cautious? Lancet 1989; 2:91-92.
63. 63. Caperna J, Barber E, Mathews WC. Estimating neutropenic risk of clinical bacteremia (CB) in HIV-infected patients by secondary analysis of clinical and laboratory data. J Investig Med 1996; 44:125A.
64. 64. Farber BF, Lesser M, Kaplan MH, et al. Clinical significance of neutropenia in patients with the human immunodeficiency virus. Infect Control Hosp Epidemiol 1991; 12:429-34.
65. 65. Moore RD, Keruly J, Chaisson RE. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995; 155: 1965-70.
66. 66. Keiser P, Higgs E, Smith J. Neutropenia is associated with bacteremia in patients infected with the human immunodeficiency virus. Am J Med Sci 1996; 312:118-22.